Home / Stocks / Advanced Enzyme Tech Ltd
ADVENZYMES

Advanced Enzyme Tech Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹296.25

Change

+15.25 (5.43%)

Open

₹281.85

Prev. Close

₹281.0

Day High

₹299.7

Day Low

₹278.8

Volume Analysis

Traded

649,251

Delivered

243,252

Delivery %

37.47%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (30.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (16.8%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹325.26 ₹312.48 ₹304.36 ₹291.58 ₹283.46 ₹270.68 ₹262.56
Fibonacci ₹312.48 ₹304.5 ₹299.56 ₹291.58 ₹283.6 ₹278.66 ₹270.68
Camarilla ₹302.0 ₹300.08 ₹298.17 ₹291.58 ₹294.33 ₹292.42 ₹290.5

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-2.57%

1 Week

+4.28%

1 Month

+14.4%

3 Months

-1.25%

6 Months

-21.03%

1 Year

-8.87%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹224.77

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

10.12%

Net margin 22.76% × asset turnover 0.39x × equity multiplier 1.14x

Company Overview

Sector

Healthcare

Market Cap

₹3,102 Cr

P/E (TTM)

19.1

ROE

10.5%

Book Value

₹149.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Advanced Enzyme Tech Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 65/100. The strongest factor is Financial Strength (100/100), while Momentum (21/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (30.0%). Strong 3-year EPS growth (16.8%).

TopFund Score — Fundamentals Quality

65/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

49

Valuation

62

Cash Flow

65

Corporate Governance

90

Momentum

21

Institutional Ownership

53

Business Quality

79

Risk & Volatility

44

Liquidity

50

From Screener.in

  • +Company is almost debt free.
  • +Company has been maintaining a healthy dividend payout of 40.9%
  • −The company has delivered a poor sales growth of 8.24% over past five years.
  • −Company has a low return on equity of 10.4% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Transcript of earnings call held on November 03, 2026 for unaudited financial results for the quarter and half year ended September 30, 2026.

6,97,582 shares extinguished under October 2026 buyback; post-extinguishment paid-up capital falls to ₹21.91 crore.

Audio recording of Q2 and half-year FY2026 results conference call available on website.

Submitted BSE/NSE application on November 3, 2026 for promoter-group reclassification of nine members.

Newspaper publication with respect to the unaudited financial results of the Company for the quarter and six months ended September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 158 161 158 155 146 169 167 186 185 172 203 192 215
Expenses + 107 107 102 103 104 114 122 129 124 123 140 139 142
Operating Profit 51 54 55 51 42 55 46 56 60 49 63 53 72
OPM % 32.0% 33.0% 35.0% 33.0% 29.0% 33.0% 27.0% 30.0% 33.0% 29.0% 31.0% 28.0% 34.0%
Other Income + 6 14 -6 7 10 8 9 9 10 20 7 11 9
Interest 1 1 1 1 1 1 1 1 1 1 1 1 1
Depreciation 9 9 9 9 9 9 10 10 10 10 10 10 11
Profit before tax 48 59 40 49 42 53 43 55 60 58 60 54 69
Tax % 27.0% 28.0% 25.0% 28.0% 21.0% 27.0% 38.0% 26.0% 25.0% 26.0% 24.0% 28.0% 26.0%
Net Profit + 35 42 30 35 33 39 27 40 45 43 45 39 51
EPS in Rs 3 4 3 3 3 3 2 4 4 4 4 3 4
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 14 13 14 5 -7 5 6 20 26 2 22 3 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 222 293 329 391 420 444 502 529 541 624 637 746 782
Expenses + 131 155 177 226 236 241 269 327 382 418 441 515 544
Operating Profit 91 138 152 165 184 203 232 203 158 206 196 230 238
OPM % 41.0% 47.0% 46.0% 42.0% 44.0% 46.0% 46.0% 38.0% 29.0% 33.0% 31.0% 31.0% 30.0%
Other Income + 1 -3 3 1 5 6 9 6 21 21 33 46 47
Interest 9 8 4 9 5 4 3 3 3 4 5 4 3
Depreciation 9 9 13 18 21 26 28 35 35 35 37 40 41
Profit before tax 74 118 137 139 162 179 210 171 140 188 187 233 240
Tax % 31.0% 35.0% 32.0% 33.0% 28.0% 26.0% 28.0% 28.0% 26.0% 27.0% 28.0% 25.0% —
Net Profit + 51 77 93 94 116 133 151 124 104 137 134 174 178
EPS in Rs 5 7 8 8 10 12 13 11 9 12 12 15 15
Dividend Payout % 4.0% 3.0% 5.0% 6.0% 6.0% 5.0% 7.0% 9.0% 11.0% 43.0% 44.0% 36.0% —
Sales growth -7 32 12 19 7 6 13 5 2 15 2 17 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 188 256 442 537 657 817 948 1,066 1,213 1,302 1,398 1,610 1,643
Borrowings + 115 101 54 67 35 28 23 35 34 47 39 32 54
Other Liabilities + 92 71 65 102 91 104 153 137 142 150 151 170 187
Total Liabilities 417 450 583 727 805 971 1,146 1,260 1,411 1,521 1,611 1,834 1,906
Fixed Assets + 287 285 421 491 495 563 601 619 649 650 679 692 724
CWIP 5 7 8 11 10 10 10 15 22 41 22 51 83
Investments 0 0 0 0 111 124 121 102 360 403 480 584 488
Other Assets + 125 158 153 226 188 275 413 524 380 427 430 507 610
Total Assets 417 450 583 727 805 971 1,146 1,260 1,411 1,521 1,611 1,834 1,906
Equity Capital 22 22 22 22 22 22 22 22 22 22 22 22 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 54 93 107 116 129 141 163 122 140 141 142 157
Cash from Investing Activity + -15 -10 -60 -60 -124 -43 -27 2 -286 -65 -89 -72
Cash from Financing Activity + -36 -63 -65 -2 -43 -39 -26 -48 -26 -59 -73 -70
Net Cash Flow 2 21 -18 54 -38 60 109 75 -171 17 -20 15
Free Cash Flow 42 88 97 105 116 90 143 95 102 94 108 105
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 88 88 105 97 70 94 94 87 112 93 103 96

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 43.62% → 43.56%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 26.88% 25.95% 36.87% 36.4% 36.31% 36.82% 25.0% 25.09% 25.62% 25.85% 25.28% 27.9%
Promoters 43.62% 43.5% 43.02% 42.95% 42.92% 43.08% 43.08% 43.08% 43.04% 43.26% 43.25% 43.56%
FII 22.54% 23.01% 12.03% 12.63% 12.57% 11.9% 23.45% 25.41% 25.85% 25.5% 26.7% 26.64%
DII 6.98% 7.56% 8.08% 8.02% 8.17% 8.19% 8.45% 6.41% 5.51% 5.41% 4.77% 1.89%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Advanced Enzyme Tech Ltd (this stock) 3,102 19.1 1.9 10.5%
Ind Swift Laboratories Lt 2,881 31.4 1.95 4.02%
Solara Active Pha Sci Ltd 3,347 70.7 2.33 -0.13%
Unichem Laboratories Ltd 3,511 29.5 1.26 3.17%
Hikal Limited 2,690 37.8 2.28 2.21%
Shukra Pharmaceuticals L 3,639 82.1 30.56 28.9%
Fredun Pharmaceuticals L 2,548 48.1 7.59 15.6%

Which Mutual Funds Hold Advanced Enzyme Tech Ltd?

Frequently Asked Questions about Advanced Enzyme Tech Ltd

Community Sentiment

What are other investors saying about Advanced Enzyme Tech Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.